CHL1 expression differentiates Hürthle cell carcinoma from benign Hürthle cell nodules
| Autor: | Maureen D. Moore, Rasa Zarnegar, Olivier Elemento, Thomas J. Fahey, Heng Liang, Akanksha Verma, Katherine D. Gray, Theresa Scognamiglio, Anna Aronova, Timothy M. Ullmann, Irene M. Min, Wei Li, Shujun Xia |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
0301 basic medicine Candidate gene Carcinoma Hepatocellular Cell law.invention CHL1 Diagnosis Differential 03 medical and health sciences 0302 clinical medicine law Cell Line Tumor Gene expression Biomarkers Tumor medicine Adenoma Oxyphilic Humans Thyroid Neoplasms Thyroid Nodule Thyroid cancer Gene Polymerase chain reaction Aged business.industry Gene Expression Profiling Liver Neoplasms General Medicine Middle Aged medicine.disease Immunohistochemistry Carcinoma Papillary 030104 developmental biology medicine.anatomical_structure Oncology Thyroid Cancer Papillary 030220 oncology & carcinogenesis Cancer research Female Surgery business Cell Adhesion Molecules |
| Zdroj: | Journal of Surgical Oncology. 118:1042-1049 |
| ISSN: | 0022-4790 |
| Popis: | Background and objectives Hurthle cell carcinoma (HCC) is an unusual and relatively rare type of differentiated thyroid cancer. Currently, cytologic analysis of fine-needle aspiration biopsy is limited in distinguishing benign Hurthle cell neoplasms from malignant ones. The aim of this study was to determine whether differences in the expression of specific genes could differentiate HCC from benign Hurthle cell nodules by evaluating differential gene expression in Hurthle cell disease. Methods Eighteen benign Hurthle cell nodules and seven HCC samples were analyzed by whole-transcriptome sequencing. Bioinformatics analysis was carried out to identify candidate differentially expressed genes. Expression of these candidate genes was re-examined by quantitative real-time polymerase chain reaction (qRT-PCR). Protein expression was quantified by immunohistochemistry. Results Close homolog of L1 (CHL1) was identified as overexpressed in HCC. CHL1 was found to have greater than 15-fold higher expression in fragments per kilobase million in HCC compared with benign Hurthle cell tumors. This was confirmed by qRT-PCR. Moreover, the immunoreactivity score of the CHL1 protein was significantly higher in HCC compared with benign Hurthle cell nodules. Conclusions CHL1 expression may represent a novel and useful prognostic biomarker to distinguish HCC from benign Hurthle cell disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text